TB-500: A Research Overview of the Thymosin Beta-4 Fragment

TB-500 is a synthetic peptide registered under CAS number 77591-33-4, supplied as a lyophilized powder reference material with the sequence Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES — a 43-residue, N-acetylated chain. Its molecular formula is C212H350N56O78S, with an average molecular weight of approximately 4963.44 g/mol. In the research literature the peptide it is modeled on is almost always named thymosin beta-4 (abbreviated Tbeta4 or TB4), a 43-amino-acid actin-sequestering protein present in many mammalian cell types; TB-500 is the name most commonly used for the synthetic peptide in non-clinical research-chemical contexts.

A point of precision matters here for anyone surveying the literature. The published, peer-reviewed studies cited on this page were conducted with thymosin beta-4 itself. TB-500 is described in research-chemical settings as the synthetic, acetylated peptide corresponding to the thymosin beta-4 sequence (or to its actin-binding domain), and the two names are frequently used interchangeably in non-clinical discussion. Because the primary studies use the thymosin beta-4 designation, the findings below are reported under that name; researchers should not assume any given TB-500 preparation is chemically identical to the material used in a specific cited study without independent analytical confirmation. The compact, highly charged structure — rich in lysine, glutamate, and aspartate residues and bearing a single methionine — is relevant to reconstitution and buffer selection. The full analytical profile (formula, mass, purity specification, and certificate-of-analysis methodology) is documented separately on the TB-500 chemistry data sheet.

The research record TB-500 draws on is the thymosin beta-4 literature, and it is overwhelmingly preclinical. Thymosin beta-4 was originally characterized as a thymic peptide and later recognized as one of the most abundant intracellular actin-sequestering peptides in mammalian cells. From the late 1990s onward, a body of work — much of it associated with researchers including Kleinman, Sosne, Goldstein and colleagues — reported activity in wound-healing, angiogenesis, cardiac, neural, and ophthalmic injury models, the large majority in rodents or in cultured cells.

It is important to characterize this evidence base accurately. The bulk of thymosin beta-4 publications are rodent in-vivo studies or in-vitro cell experiments. Unlike many research peptides, however, thymosin beta-4 has also reached controlled human clinical testing in specific niches: review literature reports it was evaluated and described as safe and well tolerated in phase 2 dermal wound trials (Kleinman et al., 2016; PMID 27450738), and the ophthalmic formulation RGN-259 progressed to a randomized, placebo-controlled, double-masked phase III trial in neurotrophic keratopathy (Sosne et al., 2022; PMID 36613994). These clinical programs are reported here purely as research context — to characterize where the molecule has and has not been studied in humans — and not as any indication of use. A structured, citation-level treatment of the literature is maintained on the TB-500 studies library, while a thematic summary organized by research domain is on the TB-500 research findings page.

No single mechanism fully accounts for the range of effects reported in thymosin beta-4 studies, and the mechanisms below are drawn from preclinical work and a small number of human investigations. They describe hypotheses and observations in defined systems, not established pharmacology in people.

The foundational molecular property is actin binding. Thymosin beta-4 is an actin-sequestering peptide, and much of the mechanistic discussion frames its downstream effects — cell migration, tissue remodeling — as flowing from its regulation of the actin cytoskeleton. The most consistently reported functional consequence is promotion of cell migration: in Boyden-chamber assays, thymosin beta-4 acted as a chemoattractant for human umbilical vein endothelial cells, stimulating directional migration four- to sixfold over medium-only controls (Malinda et al., 1997; PMID 9194528).

A second strand is matrix remodeling. In mouse dermal wounds, thymosin beta-4 increased expression of several matrix metalloproteinases, including MMP-2 and MMP-9, by several-fold over control early after wounding (Philp et al., 2006; PMID 16607611), a pathway the authors linked to the cell migration and tissue reorganization needed for repair. A related observation is its effect on connective-tissue organization: in rat incisional wounds, local thymosin beta-4 was associated with more organized, mature collagen fibers and a reduced appearance of myofibroblasts relative to the randomly organized fibers seen in controls (Ehrlich et al., 2010; PMID 20536458).

In the cardiac setting, a distinct survival-signaling mechanism was reported. After coronary artery ligation in mice, thymosin beta-4 treatment was associated with up-regulation of integrin-linked kinase (ILK) and Akt activity and enhanced early cardiomyocyte survival, with the peptide forming a functional complex with PINCH and ILK (Bock-Marquette et al., 2004; PMID 15565145). Together these strands — actin regulation, pro-migratory and angiogenic activity, MMP-mediated remodeling, and ILK/Akt survival signaling — represent the principal mechanistic hypotheses investigators cite, rather than a single unified pathway.

The thymosin beta-4 literature clusters into a few recurring domains. The summaries below report what specific studies observed in their experimental systems; they are not claims about human outcomes, and where human trials are noted they are described only as research context.

Dermal wound healing is the most developed domain. In full-thickness rat dermal wounds, topical thymosin beta-4 increased the rate of wound contraction and was associated with increased angiogenesis and collagen deposition relative to untreated controls (Malinda et al., 1999; PMID 10469335). A later review reported that thymosin beta-4 increased the rate of dermal healing across multiple preclinical models, including diabetic and aged animals, and was reported as safe and well tolerated in phase 2 clinical trials for pressure, stasis, and epidermolysis bullosa wounds (Kleinman et al., 2016; PMID 27450738).

Angiogenesis and cardiac repair form a second domain. The endothelial-migration finding (PMID 9194528) underpins the angiogenic hypothesis, and the cardiac-ligation study reported improved cardiac function alongside enhanced cardiomyocyte survival via ILK/Akt signaling (Bock-Marquette et al., 2004; PMID 15565145).

Musculoskeletal and connective-tissue models contribute further. In a rat medial collateral ligament injury model, local administration of thymosin beta-4 was associated with more uniformly organized collagen fiber bundles and improved biomechanical properties at four weeks versus controls (Xu et al., 2013; PMID 23523891), consistent with the connective-tissue organization reported in incisional wounds (Ehrlich et al., 2010; PMID 20536458).

Neural injury is a fourth domain. In a rat embolic middle cerebral artery occlusion stroke model, thymosin beta-4 given 24 hours post-stroke was associated with significant improvement in neurological function scores versus saline controls (Morris et al., 2010; PMID 20627173). In a rat controlled cortical impact traumatic brain injury model, treatment initiated six hours post-injury was associated with improved sensorimotor and cognitive recovery and increased neurogenesis in the dentate gyrus (Xiong et al., 2012; PMID 22324420). A review summarized improved neurological outcome across the authors' embolic stroke, multiple sclerosis, and traumatic brain injury models (Morris et al., 2012; PMID 23045978).

Ophthalmic and hair-follicle models round out the record. Thymosin beta-4 (as RGN-259) was associated with rapid corneal reepithelialization and reduced corneal inflammation across ophthalmic studies (Sosne et al., 2016; PMID 27450739); in a human phase III neurotrophic keratopathy trial, complete healing of persistent epithelial defects occurred in 60% of treated subjects versus 12.5% of placebo at day 29, a result approaching but not reaching statistical significance, with no significant adverse effects (Sosne et al., 2022; PMID 36613994). Separately, in normal rats and mice, thymosin beta-4 was associated with accelerated hair growth, attributed to increased migration and differentiation of hair follicle stem cells (Philp et al., 2004; PMID 14657002). For a fuller, domain-organized treatment, see the TB-500 research findings page; for study-by-study citations and evidence grading, see the TB-500 studies library.

The questions below recur most often when investigators evaluate TB-500 for laboratory work. They are answered in a research-context, regulatory, and handling frame — not as guidance for human or veterinary use.